Hannah Clarke

Nadofaragene firadenovec received FDA approval in December 2022 for the treatment of patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.

In total, the study plans to enroll approximately 100 BCG-unresponsive NMIBC CIS patients across 15 clinical study sites in the US and Canada.

"While preliminary in nature, these data provide a compelling rationale for consideration of PSMA PET as an alternative staging modality at the time of primary diagnosis," wrote the authors.

"While alkaline water products have a higher pH than regular water, they have a negligible alkali content–which suggests that they can't raise urine pH enough to affect the development of kidney and other urinary stones," says Roshan M. Patel, MD.

The phase 1/2 study is scheduled to commence in the first half of 2024.

The oral TRT study plans to enroll 20 male patients aged 18 to 49 years who meet the American Urological Association’s criteria for hypogonadism and who have not previously used TRT.

The coverage policy went into effect on December 28, 2023.

The facility will increase the production capacity of 177Lu-PSMA-617 to 250,000 doses in 2024 and beyond.

Immunotherapy initiation within 1 month of death for patients with renal cell carcinoma increased from 0.5% to 2.6% over the course of the study.

The phase 1/2a CYPIDES trial assessed the safety and preliminary efficacy of ODM-208 in heavily pretreated patients with metastatic castration-resistant prostate cancer.

The payment rate for the prostate cancer test went into effect on January 1, 2024.

"The future of quality measurement is multiple different inputs to give us the best picture possible of the care we provide," says Timothy D. Lyon, MD, FACS.

The open-label CaRe PC trial plans to enroll up to 30 adult patients with mCRPC, who will be treated across 3 dose levels of INKmune.

Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.

As the year comes to a close, we revisit some of this year’s top content on kidney stones.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia in urology.

As the year comes to a close, we revisit some of this year’s top content on kidney cancer.

"We found that less than 5% of people with incontinence had received a surgical intervention for their incontinence within a year of the survey," says Giulia I. Lane, MD, MS.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging agents in urology.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

The study is set to begin in January 2024.

"This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer,” says Alicia K. Morgans, MD, MPH.

"If the diversity and robust functional potential of the healthy human microbiome is repeatedly assaulted by the average Westernized lifestyle via antibiotic exposure, diet, and other environmental factors, kidney stone prevalence will continue to increase," the authors write.

A response by the FDA is expected by February 2024.

Overall, 177Lu-PNT2002 demonstrated a median radiographic progression-free survival of 9.5 months, compared with 6.0 months among patients who were treated with an ARPI.

The BLA submission is supported by findings from the phase 3 ZIRCON study, which demonstrated high specificity and sensitivity of the agent for PET/CT imaging of ccRCC.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.

The approval is supported by findings from the phase 3 LITESPARK-005 trial.